Also found in: Dictionary, Thesaurus, Wikipedia.


1. A salt or ester of n-caproic acid.
2. USAN-approved contraction for hexanoate, CH3(CH2)4COO-.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
Because of some initial medication access issues after the launch of an FDA-approved hydroxyprogesterone caproate injection, while acknowledging a "greater assurance of safety" with the use of the FDA-approved product, for a brief period of time in 2011 the FDA announced "enforcement discretion" regarding its usual prohibition of prescribing compounded medications when an FDA-approved drug was available, stating it could revisit the issue at any time.
Compounds reduced by crop reduction were phenyl ethyl alcohol, octanoic acid, isoamyl alcohol, ethyl caproate, 2-phenylethyl acetate and decanoic acid (2011 only).
The effect of 17 alpha hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population.
Hydroxyl progesterone caproate is unlikely to affect an infectious process but in our study it provided protection against preterm delivery in women with history of preterm labour.
On March 30, the FDA announced that "to support access to this important drug, at this time and under this unique situation, [the agency] does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate" unless the product is unsafe or not being produced in accordance with standards.
From these findings researchers concluded that omega 3 supplementation offered no benefit in reducing preterm birth among women receiving 17 alpha-hydroxyprogesterone caproate who have a history of preterm delivery.
monodon (fed) 0.39 Spectrophotometric assay, 4-[rho]-nitrophenol caproate P.
Two double-blind, placebo-controlled studies assessed the use of 17 [alpha]-hydroxyprogesterone caproate in preventing premature labor in high-risk populations.
The drug, 17-alpha-hydroxy-progesterone caproate (17P), is a natural metabolic product of the female hormone progesterone.
The new treatment, weekly shots of a hormone called 17-alpha-hydroxyprogesterone caproate, or 17P, were started at sixteen to eighteen weeks of pregnancy and stopped at thirty-six weeks.
Nonspecific esterase activity increased with increasing substrate concentration to reach a maximum activity at 1 mM 4-nitrophenol caproate (4-NPC) solution.
The sweeteners studied were sucrose, fructose and aspartame; the flavor substances were ethyl caproate, pinene and cinnamic acid.